Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why

Core Viewpoint - Liquidia Corporation (NASDAQ:LQDA) is identified as a high growth healthcare stock with significant potential in the pulmonary hypertension market, supported by recent price target increases from Wells Fargo and Oppenheimer [1][2]. Group 1: Price Target Updates - Wells Fargo raised the price target for Liquidia Corporation to $51 from $44, maintaining an Overweight rating, citing a positive outlook for the pulmonary hypertension market and competitive positioning of L606 against Insmed's TPIP [1]. - Oppenheimer increased its price target for Liquidia to $19 from $16, reiterating an Underperform rating, while acknowledging the strong early launch of YUTREPIA, which generated net product sales of $148.3 million in fiscal year 2025 [2]. Group 2: Product Development and Market Position - Liquidia Corporation is engaged in developing and commercializing biopharmaceutical products through its subsidiary, utilizing PRINT technology for novel product development [3]. - The company’s early success with YUTREPIA in the pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease markets indicates a growing demand, which Oppenheimer previously underestimated [2].